Analyst Available to Comment on Acquisition's Impact on Age-Related                        Macular Degeneration Market  

Regina Cebula, analyst at Decision Resources, is available to discuss the impact of Merck's acquisition of San Francisco-based Sirna Therapeutics Inc. for $1.1 billion -- a deal that moves Merck into a leading position in the field of RNA interference (RNAi) technology.

Ms. Cebula is the author of the recent Age-Related Macular Degeneration report from Decision Resources which covers Sirna-027, an RNAi agent currently moving into Phase II clinical development.

  Ms. Cebula can discuss the following:    *  The benefits Merck will reap in the acquisition of Sirna Therapeutics      and how this deal puts Merck into a leading market position with a      strong competitive advantage.    *  The significant impact on Merck's pipeline as the acquisition gives      Merck a new, cutting-edge technology that will likely prove beneficial      in previously difficult-to-treat disease areas such as ocular      indications, respiratory disorders, cancer, and viral infections.    *  Sirna-027's likely emergence as a beneficial maintenance therapy for      Wet Age-Related Macular Degeneration.  

Regina E. Cebula, M.S., is an analyst at Decision Resources, Inc. Prior to joining Decision Resources, Ms. Cebula worked as a medicinal chemist developing drug discovery technologies and small-molecule drug inhibitors for various oncologic and anti-infective programs at GPC Biotech, Novartis Institutes for Biomedical Research, and Biogen Idec. Ms. Cebula holds a B.S. in chemistry from Saint Joseph's University and an M.S. in synthetic organic chemistry from the University of New Hampshire.

To speak with Ms. Cebula regarding Merck's acquisition of Sirna, please contact Chris Comfort at 781-296-2597 or

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Christopher Comfort   781-296-2597 

PRNewswire -- Oct. 31
First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources, Inc.

Rising Number of Morbidly Obese Patients Requires U.S. Hospitals to Purchase New Equipment

View Now